BioSpace News Archive

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.

Mindera Corporation announced a $12.6M Series A-2 capital raise. The round was led by Mountain Group Partners, Rockmont Investments, and Scientific Health Development.

Ryvu Therapeutics (WSE: RVU) today announced that three abstracts demonstrating clinical and pre-clinical activity of its selective CDK8/19 inhibitor RVU120 (SEL120) and its selective PIM/FLT3 inhibitor SEL24(MEN1703) have been accepted for presentation at the Annual European Hematology Association (EHA) 2021 Virtual Congress,

Philogen S.p.A. (BIT:PHIL) - a listed clinical-stage biotechnology company focused on the development of innovative medicines based on tumor targeting antibodies and small molecule ligands, is pleased to announce progress updates for its fully-owned immunocytokine and small molecule programs.

Adverum Biotechnologies, Inc. announced that, based on a preliminary vote count provided by its proxy solicitors following its 2021 Annual Meeting of Stockholders, stockholders have voted to re-elect all three of Adverum’s highly qualified director nominees – Dawn Svoronos, Reed V. Tuckson, M.D. and Thomas Woiwode, Ph.D.

Moffitt Cancer Center is honored to earn the No. 3 position on DiversityInc’s Top Hospitals and Health Systems for 2021.

Additional Funding and Scientific Expertise Advance Company’s Clinical Development and Efforts Towards Commercialization

Grady Memorial Hospital’s Marcus Trauma Center has again earned the highest national trauma recognition — Level I Trauma Center, verified by the American College of Surgeons.

MCRA, LLC, the leading privately held medical device and biologics advisory firm and Clinical Research Organization (CRO) integrating U.S. and International Regulatory, Clinical Research, Reimbursement, Healthcare Compliance, Quality Assurance, and Medical Device Cybersecurity,

Summit Therapeutics Inc. (NASDAQ: SMMT) announced today the successful closing of its fully subscribed rights offering and the associated results.